Atomoxetine to Treat Adolescents With Coexisting Alcohol and Other Substance Use Disorder and ADHD

University of Pittsburgh24 enrolled

Overview

The purpose of this study is to compare the effectiveness and safety of atomoxetine in the treatment of adolescents with coexisting alcohol or substance use disorders and Attention Deficit Hyperactivity Disorder (ADHD).

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Substance Use Disorders Attention Deficit Hyperactivity Disorder

Interventions

AtomoxetineDRUG

Eligibility

Sex: ALLMin age: 13 YearsMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adolescents, ages 13-18 * Meets criteria for alcohol and/or substance use disorder and attention deficit hyperactivity disorder. Exclusion Criteria: * Adolescents who are pregnant. * Have a history of seizure disorder, other neurological or medical disorder for which medication treatment may present a considerable risk. * History of pervasive development disorder, schizophrenia or other psychotic disorders, organic mental disorders or eating disorders. * Currently on other psychotropic medications from which discontinuation would present a significant risk. * A current episode of major depressive disorder or a diagnosis of bipolar disorder. * Diagnosis of dependence for any substance other than marijuana. * Adolescents with a full-scale IQ below 80.

Locations (1)

Western Psychiatric Institute and Clinic

Pittsburgh, Pennsylvania, United States

Outcomes

Primary Outcomes

decrease in ADHD symptoms

decrease in the quantity and frequency of alcohol and other substance use

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.